Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 December;63(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 December;63(4):387-93

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 December;63(4):387-93

DOI: 10.23736/S1824-4785.18.02985-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer

Daniele A. PIZZUTO 1 , Salvatore ANNUNZIATA 1, Francesco P. IERIA 1, Carmelo CALDARELLA 2, Maria A. ISGRÒ 3, Valerio LANNI 2, Gaia BENCIVENGA 4, Vittoria RUFINI 1, Alessandro GIORDANO 1

1 Unità Operativa Complessa di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, Italy; 2 Unit of Nuclear Medicine, Unità Operativa Complessa di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; 3 Chemical-Clinical and Hematologic Analysis Laboratory, Circolo e Fondazione Macchi Hospital, Varese, Italy; 4 PET-CT Center, Unità Operativa Complessa di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy



BACKGROUND: Metastatic spreading to the lungs is a negative prognostic factor in patients with prostate cancer (PC). Aim of our study was to assess the prevalence of lung PC metastases in patients with fluorine-18 fluoroethyl-choline (F-18-FECh) PET-CT positive lung lesions and the role of Gleason Score (GS) and common biochemical markers in predicting metastatic spreading to the lungs.
METHODS: We retrospectively evaluated the scans of 1283 patients ongoing (F-18-FECh) PET-CT for PC between May 2010 and July 2014. Patients with lung lesion with F-18-FECh uptake were included. Data concerning GS at diagnosis, “trigger” prostate-specific antigen (PSAtr), PSA doubling time (PSAdt), PSA velocity (PSAvel) and ongoing androgen deprivation therapy were collected. PET-CT findings were confirmed by histology or follow-up (FU) and classified as follows: inflammation, primary lung cancer or metastases from tumor other than PC, and lung metastases from PC.
RESULTS: Twenty-two patients with F-18-FECh positive lung lesion and available histology or FU were identified. PSAdt was significantly (P=0.029) shorter in patients with lung metastases from PC (median PSAdt 1.7 months, interquartile range [IQR] 1.5-4.1 months) than in patients without lung PC relapse (median PSAdt 6.7 months, IQR 3.9-7.8); PSAvel was significantly (P=0.019) higher in patients with lung metastases from PC (median PSAvel 3.2 ng/mL/month, IQR 0.65-6.65 ng/mL/month) than in patients without lung PC relapse (median PSAvel 0.3 ng/mL/month, IQR 0.2-0.5 ng/mL/month). Patients with lung metastases from PC had significantly (P=0.006) higher GS at diagnosis (median GS 8) than the other ones (median GS 7).
CONCLUSIONS: Our analysis shows that the prevalence of F-18-FECh positive lung metastases in patients with PC, especially with higher GS at diagnosis, is higher in presence of a steady increase in PSA values, confirmed by higher PSAvel and shorter PSAdt.


KEY WORDS: Prostate; Lung; Neoplasm metastasis; Choline

top of page